Reperfusion therapy for disabling minor stroke with large vessel blockage
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a precise treatment to restore blood flow in people who had a mild but disabling stroke up to 24 hours earlier, using mechanical clot removal or clot-busting medication. The goal is to reduce long-term disability by reopening the blocked vessel while protecting healthy brain tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have had an ischemic stroke (a blocked blood vessel in the brain) that started 4.5 to 24 hours before you would be treated.
- Your stroke should cause a noticeable disability, such as complete vision loss on one side, severe speech problems, neglect, limb weakness, or trouble with daily activities like bathing, walking, or eating.
- Imaging must show a blockage in a major brain artery (like the internal carotid or middle cerebral artery).
- You must not have had a major stroke or disability before this one, and you must not have had a stroke in the last 3 months.
- You cannot be taking certain blood thinners or have certain other serious conditions (like recent major surgery or very high blood pressure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a clot-busting medication (tenecteplase) directly into the artery after an incomplete clot-removal procedure can improve blood flow and outcomes in people with large vessel strokes. It aims to help those who had partial reopening after mechanical thrombectomy.
This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the blocked blood vessel in the brain can help people with a medium-sized vessel occlusion stroke. The drug may help restore blood flow and reduce disability, and it is given within 24 hours of symptom onset.
This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.
This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.
This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.
Hear when a new Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.